Compare Extra Space Storage, Inc. (EXR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Incyte Corporation — how do they compare? Extra Space Storage, Inc. trades at $146.41 (market cap $30.96B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Extra Space Storage, Inc. is the larger of the two by market cap, and Extra Space Storage, Inc. pays a 4.42% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| EXR | INCY | |
|---|---|---|
Market Cap | $30.96B | $24.54B |
Sector | Real Estate | Health |
52-Week High | $152.85 | $129.93 |
52-Week Low | $126.67 | $81.61 |
Enterprise Value | $44.68B | $20.04B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $146.77, up 0.08% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating FFO estimates, and maintains robust fundamentals with a 27.79% net income margin. Recent news highlights a 52-week high of $155.80 reached in late July 2026, though the stock has since pulled back slightly.
The outlook is mixed; solid earnings growth and a secure 4.3% dividend yield support the bull case, but high valuation multiples (P/E of 32.35) and increasing debt levels pose risks. Analyst consensus is a 'Hold' with a $157.25 price target, suggesting limited near-term upside from current levels amid competitive pressures.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
